Patients’ Right to Know Their Medication Act of 2025
Summary
The "Patients' Right to Know Their Medication Act of 2025" aims to amend the Federal Food, Drug, and Cosmetic Act. It mandates standardized, printed patient medication information (PMI) be included with prescription drugs. This bill seeks to improve patient safety and reduce healthcare costs associated with adverse drug events.
Expected Effects
The act would require drug manufacturers to provide clear, standardized paper-based information. This includes details on usage, risks, and potential side effects. The FDA would be responsible for regulating the content and format of this information.
Potential Benefits
- Improved patient understanding of medications.
- Reduction in adverse drug events and associated healthcare costs.
- Standardized information format for all prescription drugs.
- Ensured access to medication information for patients without electronic access.
- Potential for better medication adherence and compliance.
Potential Disadvantages
- Increased costs for drug manufacturers due to printing and packaging requirements.
- Potential delays in the approval process for new drugs due to additional regulatory hurdles.
- Possible information overload for patients with lengthy medication information sheets.
- Environmental concerns related to increased paper usage.
- Risk of outdated information if updates are not timely.
Most Disadvantaged Areas:
Constitutional Alignment
The bill aligns with the general welfare clause of the US Constitution, as it aims to improve public health and safety. Congress has the power to regulate interstate commerce, which includes the regulation of drugs and medications. This is consistent with Article 1, Section 8 of the Constitution.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).